BioVaxys Technology Corp.
BVAXF · OTC
7/31/2025 | 4/30/2025 | 1/31/2025 | 10/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.14 | 0.06 | -0.01 |
| FCF Yield | -11.79% | -12.22% | -5.02% | -6.21% |
| EV / EBITDA | 0.00 | -6.85 | -14.68 | -10.81 |
| Quality | ||||
| ROIC | 24.49% | 49.67% | 0.00% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.16 | 0.01 | 0.83 | 0.37 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.75% | -19.26% | 12.10% | -146.36% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -0.10 | 0.07 | 0.10 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |